Inflammation in Parkinson's diseases and other neurodegenerative diseases: Cause and therapeutic implications

Current Pharmaceutical Design

Volumn 13, Issue 18, 2007, Pages 1925-1928

  Wilms, H ^a   Zecca, L ^b   Rosenstiel, P ^a   Sievers, J ^a   Deuschl, G ^a   Lucius, R ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

Microglia; Neuroinflammation; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; BENZODIAZEPINE; CLONAZEPAM; DEXAMETHASONE; DIAZEPAM; DICLOFENAC; HYDROCORTISONE; I KAPPA B; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPHILIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MANGANESE; MIDAZOLAM; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROMELANIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOPAMINE; PARACETAMOL; PHOSPHODIESTERASE IV INHIBITOR; PIOGLITAZONE; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CELL ACTIVATION; CHEMOTAXIS; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPARKINSON AGENTS; CELL DEATH; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MELANINS; MICROGLIA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 34347357758     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780858429     Document Type: Review

References (44)

1. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998; 352: 1344-6.
2. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993; 43: 1150-8.
3. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998; 50: 1346-50.
4. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
5. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4- phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine. Life Sci 1985; 36: 2503-8.
6. Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K. Experimental models of Parkinson's disease: insights from many models. Lab. Anim Sci 1999; 49: 363-71.
7. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-6.
8. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999; 823: 1-10.
9. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46: 598-605.
10. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574-6.
11. Banati RB, Gehrmann, J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia 1993; 7: 111-8.
12. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995; 21: 195-218.
13. Giulian D, Corpuz M. Microglial secretion products and their impact on the nervous system. Adv Neurol 1993; 59: 315-20.
14. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann, P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22: 1763-71.
15. Mihm MJ, Schanbacher BL, Wallace BL, Wallace LJ, Uretsky NJ, Bauer JA. Free 3-nitrotyrosine causes striatal neurodegeneration in vivo. J Neurosci 2001; 21: RC149.
16. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996; 72: 355-63.
17. Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995; 64: 936-9.
18. Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 1999; 274: 34621-8.
19. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. mmunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994; 172: 151-4.
20. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992; 581: 283-91.
21. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992; 59: 1080-9.
22. Ishikawa A, Takahashi H. Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J Neurol 1998; 245: 4-9.
23. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. Activation of microglia by human neuromelanin is NF-κB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003; 17: 500-2.
24. McNaught KS, Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 1999; 73: 2469-76.
25. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002; 81: 1285-97.
26. Castano A, Herrera AJ, Cano, J, Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 2002; 81: 150-7.
27. Chen, H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60: 1059-64.
28. Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998; 71: 1635-42.
29. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999; 156: 50-61.
30. Matsuura K, Kabuto H, Makino H, Ogawa N. Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice. Neurosci Lett 1997; 230: 191-4.
31. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
32. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000; 20: 558-67.
33. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000; 20: 6862-7.
34. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82: 615-24.
35. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 14669-74.
36. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001; 909: 187-93.
37. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 1997; 50: 345-53.
38. Banati RB, Newcombe J, Gunn RN, Cagnin, A, Turkheimer F, Heppner F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123: 2321-37.
39. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-7.
40. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with (11)C(R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 2006; 21(1): 89-93.
41. Wilms H, Claasen J, Rohl C, Sievers J, Deuschl G, Lucius R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis 2003; 14: 417-24.
42. Guilloteau D, Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 2005; 11(25): 3237-45.
43. Hayley S, Anisman H. Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates. Curr Pharm Des 2005; 11(8): 947-62.
44. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005; 11(8): 999-1016.